Information Provided By:
Fly News Breaks for January 11, 2016
GHDX
Jan 11, 2016 | 05:20 EDT
Piper Jaffray analyst William Quirk downgraded Genomic Health to Neutral on expectations the company's revenue growth in 2017 will slow from 2016 amid tougher comps. Quirk believes private payer reimbursement will be limited given his caution stance on the company's test's ability to predict disease recurrence. He cut his price target for the shares to $32 from $36.
News For GHDX From the Last 2 Days
There are no results for your query GHDX